As of November 7, 2026, Madrigal Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 28, 2026 to August 12, 2026, naming 1 appointment. The latest filing names John C. Reed, appointed (Form 8-K, August 12, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Madrigal Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: John C. Reed · Effective: 2026-08-11 · 8-K, 2026-08-12
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-17
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-28
Madrigal Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-28 to 2026-08-12. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Madrigal Pharmaceuticals, Inc. files it.
Also on the record for Madrigal Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 9.99% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 8.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by PAULSON & CO. INC. | 6.1% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by PAULSON & CO. INC. | 7.5% of the class | 5%+ stakes | Source |
| December 12, 2025 | Stake report, Schedule 13D/A, by Paul A Friedman, M.D. | 7.8% of the class | 5%+ stakes | Source |
| December 12, 2025 | Stake report, Schedule 13D/A, by Rebecca Taub, M.D. | 7.8% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 8.3% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Madrigal Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Madrigal Pharmaceuticals, Inc. and the records around it.
Madrigal Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Paul A Friedman, M.D. also filed stake reports on 1 other company: MADRIGAL PHARMACEUTICALS, INC. (Dec 2025)
- Rebecca Taub, M.D. also filed stake reports on 1 other company: MADRIGAL PHARMACEUTICALS, INC. (Dec 2025)
- PAULSON & CO. INC. also filed stake reports on 5 other companies: INTERNATIONAL TOWER HILL MINES LTD (Apr 2026), Bausch Health Companies Inc. (Aug 2025), NOVAGOLD RESOURCES INC (Aug 2025)
Watch Madrigal Pharmaceuticals, Inc.
Get an email when Madrigal Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Madrigal Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Madrigal Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Madrigal Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-12 | In | 2026-08-11 | 8-K, 2026-08-12 | ||
| 2026-06-17 | Reported | not named in the filing | 8-K, 2026-06-17 | ||
| 2026-04-28 | Reported | not named in the filing | 8-K, 2026-04-28 |
New leaders reset buying decisions — get the Full Report on Madrigal Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Madrigal Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at Madrigal Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: John C. Reed, effective 2026-08-11
On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.
- Dr. Reed will serve as a Class II director with a term expiring at the annual meeting of stockholders to be held in 2027 or until his successor is duly elected and qualified.
- Dr. Reed has been appointed to the Science and Technology Committee of the Board.
- As a non-employee director, in accordance with the Company's Non-Employee Director Compensation Policy, Dr. Reed will receive an annual cash retainer of $50,000.
- He will also be entitled to $10,000 annually for his service on the Science and Technology Committee.
- In addition, in connection with his appointment to the Board, Dr. Reed will receive an equity grant with a value of $675,000, consisting of 50% nonqualified stock options ("Options") to purchase shares of common stock of the Company (the "Option Grant") and 50% restricted stock units of the Company (the "RSU Grant"), in each case pursuant to the Company's 2026 Stock Plan.
- The Option Grant will vest as to 50% of such Options on the first anniversary of the grant date and 12.5% of such Options on the last day of each successive three-month period for four successive three-month periods, subject to Dr. Reed's continued service on such dates.
- Half of the shares underlying the RSU Grant will vest on the first anniversary of the grant date and the remaining half will vest on the second anniversary of the grant date, subject to Dr. Reed's continued service on such dates.
Reported
A participant's account balance will be credited with deemed earnings in accordance with the earnings crediting options elected by the participant from time to time.
- 2026 Stock Plan On June 17, 2026, at the annual meeting of stockholders (the "Annual Meeting") of Madrigal Pharmaceuticals, Inc. (the "Company"), the Company's stockholders approved the Madrigal Pharmaceuticals, Inc. 2026 Stock Plan (the "2026 Stock Plan"), which was previously adopted by the Company's Board of Directors (the "Board").
- Non-Qualified Deferred Compensation Plan On June 16, 2026, the Board approved the adoption of the Madrigal Pharmaceuticals, Inc. Nonqualified Deferred Compensation Plan (the "Deferred Compensation Plan") for certain key management or highly compensated employees, including the Company's named executive officers, and non-employee members of the Board as selected by the administrator of the Deferred Compensation Plan, which is the Compensation Committee (the ''Committee'') or its delegate.
- The Deferred Compensation Plan will be effective on August 1, 2026.
- The Deferred Compensation Plan is an unfunded, nonqualified deferred compensation plan.
- Participants that are employees may defer, on a pre-tax basis, up to 60% of their base salary and up to 95% of their annual cash performance bonus to be earned in the following year.
- Participants who are non-employee directors may defer all or a portion of their cash Board service fees and equity grants received by a director for service on the Board and its committees.
Reported
Each of Mr. Baker and Mr. Brennan resigned from his position as a Class III and Class II director, respectively, subject to and conditioned upon his simultaneous reappointment as a Class I director.
- On April 22, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") completed a process to reclassify the membership of the Board's three classes of directors to achieve a more equal apportionment of membership among the three classes following its Annual Meeting of Stockholders to be held on June 17, 2026 (the "2026 Annual Meeting").
- The Board determined that one of its members from Class III (with a term expiring at the 2028 Annual Meeting of Stockholders) and one of its members from Class II (with a term expiring at the 2027 Annual Meeting of Stockholders) should be reclassified to Class I (with a term expiring at the 2026 Annual Meeting).
- Accordingly, effective April 22, 2026, Julian C. Baker and Daniel J. Brennan have been reclassified as Class I directors of the Board.
- The Board accepted each resignation and simultaneously reappointed each of Mr. Baker and Mr. Brennan as a Class I director.
- The resignation and reappointment of Mr. Baker and Mr. Brennan was effected solely for the purpose of reclassifying the members of the Board into three classes of as equal size as possible, and for all other purposes, the service of Mr. Baker and Mr. Brennan on the Board is deemed to have continued uninterrupted.
- There were no changes to Mr. Baker's or Mr. Brennan's committee assignments as a result of the reclassification.
Tools for this story
Each opens in a new tab, filled in for Madrigal Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.